Eric Majchrzak focuses his practice on matters related to patent and commercial litigation for clients in the pharmaceutical and life sciences industries. He has extensive experience representing companies in a wide range of matters including complex patent infringement litigation arising under the Hatch-Waxman Act and the Biologics Price Competition and Innovation Act, as well as commercial litigation. In addition, Eric conducts due diligence investigations with regards to patent validity and infringement.
Recent representative matters include:
- Representing a diagnostics company in the Federal Circuit concerning a patent dispute related to an innovative myasthenia gravis diagnostic method.
- Representing a pharmaceutical company in the Eastern District of Virginia and the Federal Circuit in a declaratory judgment action concerning humanized antibody technology. The district court held the client’s product to be non-infringing and the Federal Circuit affirmed.
- Representing pharmaceutical companies in Hatch-Waxman litigation in the District of Delaware and on-appeal in the Federal Circuit.
- Representing a pharmaceutical company, as amicus curiae, in a Federal Circuit appeal concerning the patent eligibility and validity of antibody technology.
Prior to joining Fenwick & West, Eric was an associate in the intellectual property group of a leading international law firm.